US 12,421,323 B2
Multispecific antibody molecules comprising lambda and kappa light chains
Andreas Loew, Boston, MA (US); Brian Edward Vash, Cambridge, MA (US); and Stephanie J. Maiocco, Arlington, MA (US)
Assigned to MARENGO THERAPEUTICS, INC., Cambridge, MA (US)
Filed by Marengo Therapeutics, Inc., Cambridge, MA (US)
Filed on May 12, 2023, as Appl. No. 18/316,804.
Application 18/316,804 is a division of application No. 16/335,822, granted, now 11,673,971, previously published as PCT/US2017/053053, filed on Sep. 22, 2017.
Claims priority of provisional application 62/399,319, filed on Sep. 23, 2016.
Claims priority of provisional application 62/474,569, filed on Mar. 21, 2017.
Prior Publication US 2023/0272119 A1, Aug. 31, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/46 (2006.01); A61P 35/00 (2006.01); C07K 16/00 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01); C07K 16/44 (2006.01)
CPC C07K 16/468 (2013.01) [A61P 35/00 (2018.01); C07K 16/00 (2013.01); C07K 16/246 (2013.01); C07K 16/2818 (2013.01); C07K 16/2878 (2013.01); C07K 16/40 (2013.01); C07K 16/44 (2013.01); C07K 2317/31 (2013.01); C07K 2317/515 (2013.01); C07K 2317/567 (2013.01)] 13 Claims
OG exemplary drawing
 
1. An antibody molecule comprising four non-contiguous polypeptides, wherein:
(a) a first heavy chain polypeptide (HCP1) comprising a sequence having at least 95% sequence identity to the sequence of amino acids 120-449 of SEQ ID NO: 164;
(b) a kappa light chain polypeptide (KLCP) comprising a sequence having at least 95% sequence identity to the sequence of amino acids 111-213 of SEQ ID NO: 165;
(c) a second heavy chain polypeptide (HCP2) comprising a sequence having at least 95% sequence identity to the sequence of amino acids 121-450 of SEQ ID NO: 166; and
(d) a lambda light chain polypeptide (LLCP) comprising a sequence having at least 95% sequence identity to the sequence of amino acids 111-216 of SEQ ID NO: 167;
wherein the HCP1 and the HCP2 are a knob and hole pair; and wherein:
(A) (i) the KLCP binds to the HCP1 with a higher affinity than the affinity of the LLCP to the HCP1 and the affinity of the KLCP to the HCP2; and
(ii) the LLCP binds to the HCP2 with a higher affinity than the affinity of the KLCP to the HCP2 and the affinity of the LLCP to the HCP1; or
(B) (i) the LLCP binds to the HCP1 with a higher affinity than the affinity of the KLCP to the HCP1 and the affinity of the LLCP to the HCP2; and
(ii) the KLCP binds to the HCP2 with a higher affinity than the affinity of the LLCP to the HCP2 and the affinity of the KLCP to the HCP1.